《大行報告》瑞信:中生製藥(01177.HK)第三季收入增長穩固符預期 維持「跑贏大市」評級
瑞信發表研究報告指,中生製藥(01177.HK)第三季銷售達75億元人民幣,按年增21.3%,雖然增長強勁穩固,但仍屬預期之內。管理層重申其2022年的銷售指引,並料2023財年銷售增逾10%,較該行預期的9%為高。由於集團創新藥物的前景良好、密集的商務拓展(BD)時間表和進一步的政策風險有限,該行維持集團「跑贏大市」評級及目標價6.8元。
對於藥物penpulimab、anlotinib、Ganmei及F-627,集團目標是在2023財年達到100億元人民幣,瑞信認為目標進取。集團目標每年至少進行五次BD交易。在2022財年,公司或有另外兩筆BD交易完成。由於美國外國投資委員會(CFIUS)正在進行審查,收購生物醫藥公司F-Star的交易已延長至11月18日。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.